H. R. 2820 
One Hundred Fourteenth Congress 
of the 
United States of America 
AT THE FIRST SESSION 
Begun and held at the City of Washington on Tuesday, 
the sixth day of January, two thousand and fifteen 
An Act 
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other 
purposes. 
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Stem Cell Therapeutic and 
Research Reauthorization Act of 2015’’. 
SEC. 
2. 
REAUTHORIZATION 
OF 
THE 
C.W. 
BILL 
YOUNG 
CELL 
TRANSPLANTATION PROGRAM. 
(a) IN GENERAL.—Section 379(d)(2)(B) of the Public Health 
Service Act (42 U.S.C. 274k(d)(2)(B)) is amended— 
(1) by striking ‘‘remote collection’’ and inserting ‘‘collection’’; 
and 
(2) by inserting ‘‘including remote collection,’’ after ‘‘cord 
blood units,’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—Section 379B of the 
Public Health Service Act (42 U.S.C. 274m) is amended— 
(1) by striking ‘‘$30,000,000 for each of fiscal years 2011 
through 2014 and’’; and 
(2) by inserting ‘‘and $30,000,000 for each of fiscal years 
2016 through 2020’’ before the period at the end. 
(c) SECRETARY REVIEW ON STATE OF SCIENCE.—The Secretary 
of Health and Human Services, in consultation with the Director 
of the National Institutes of Health, the Commissioner of the Food 
and Drug Administration, and the Administrator of the Health 
Resources and Services Administration, including the Advisory 
Council on Blood Stem Cell Transplantation established under sec-
tion 379(a) of the Public Health Service Act (42 U.S.C. 274k(a)), 
and other stakeholders, where appropriate given relevant expertise, 
shall conduct a review of the state of the science of using adult 
stem cells and birthing tissues to develop new types of therapies 
for patients, for the purpose of considering the potential inclusion 
of such new types of therapies in the C.W. Bill Young Cell 
Transplantation Program (established under such section 379) in 
addition to the continuation of ongoing activities. Not later than 
June 30, 2019, the Secretary shall submit to the Committee on 
Health, Education, Labor, and Pensions of the Senate and the 
Committee on Energy and Commerce of the House of Representa-
tives recommendations on the appropriateness of such new types 
of therapies for inclusion in the C.W. Bill Young Cell Transplan-
tation Program.
H. R. 2820—2 
SEC. 3. CORD BLOOD INVENTORY. 
Section 2 of the Stem Cell Therapeutic and Research Act of 
2005 (42 U.S.C. 274k note) is amended— 
(1) in subsection (a), by striking ‘‘one-time’’; 
(2) by striking subsection (c); 
(3) by redesignating subsections (d) through (h) as sub-
sections (c) through (g), respectively; 
(4) in subsection (d) (as so redesignated)— 
(A) in paragraph (1), by striking ‘‘paragraphs (2) and 
(3)’’ and inserting ‘‘paragraphs (2), (3), and (4)’’; 
(B) in paragraph (2)(B), by striking ‘‘subsection (d)’’ 
and inserting ‘‘subsection (c)’’; and 
(C) by adding at the end the following: 
‘‘(4) CONSIDERATION OF BEST SCIENCE.—The Secretary shall 
take into consideration the best scientific information available 
in order to maximize the number of cord blood units available 
for transplant when entering into contracts under this section, 
or when extending a period of funding under such a contract 
under paragraph (2). 
‘‘(5) CONSIDERATION OF BANKED UNITS OF CORD BLOOD.— 
In extending contracts pursuant to paragraph (3), and deter-
mining new allocation amounts for the next contract period 
or contract extension for such cord blood bank, the Secretary 
shall take into account the number of cord blood units banked 
in the National Cord Blood Inventory by a cord blood bank 
during the previous contract period, in addition to consideration 
of the ability of such cord blood bank to increase the collection 
and maintenance of additional, genetically diverse cord blood 
units.’’; 
(5) in subsection (f) (as so redesignated)— 
(A) by striking paragraph (4); and 
(B) by redesignating paragraphs (5) and (6) as para-
graphs (4) and (5), respectively; and 
(6) in subsection (g) (as so redesignated)— 
(A) in paragraph (1)— 
(i) by striking ‘‘$23,000,000 for each of fiscal years 
2011 through 2014 and’’; and 
(ii) by inserting ‘‘and $23,000,000 for each of fiscal 
years 2016 through 2020’’ before the period at the 
end; and 
(B) by striking paragraph (2).
H. R. 2820—3 
SEC. 4. DETERMINATION ON THE DEFINITION OF HUMAN ORGAN. 
Not later than one year after the date of enactment of this 
Act, the Secretary of Health and Human Services shall issue deter-
minations with respect to the inclusion of peripheral blood stem 
cells and umbilical cord blood in the definition of human organ. 
Speaker of the House of Representatives. 
Vice President of the United States and
President of the Senate.